A study testing whether a GLP-1 medicine from University of Washington, semaglutide, can protect the kidneys.
- Who can join
- Adults 18+, have diabetic kidney disease, BMI 20+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 3.7 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Diabetic Kidney Disease. Also studied in: Type 1 Diabetes.
Full scientific study title: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes.
Who can join
Adults 18+, have diabetic kidney disease, BMI 20+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Adults (>=18 years) with type 1 diabetes
- Diabetes duration of >=5 years
- Persistent urine albumin-to-creatinine ratio (UACR) >= 30 mg/g, on the most recent two measurements within the prior 3 years
- Estimated glomerular filtration rate >= 20 mL/min/1.73m2
- Stable doses of drugs altering blood pressure (e.g., Angiotensin-converting enzyme inhibitor) required for at least 4 weeks prior to randomization, and requested for the duration of the trial
Key exclusion criteria
- HbA1c >9%, recent diabetic ketoacidosis, hyperosmolar hyperglycemic state or severe illness requiring hospitalization in past 30 days
- Other causes of diabetes mellitus, including type 2 diabetes and maturity-onset diabetes of the young (MODY)
- Chronic kidney disease unrelated to diabetes
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or thyroid nodule palpated by endocrinologist at screening
- Personal history of pancreatitis
Where this study is enrolling
This trial has 3 sites across 2 states. Contact a site coordinator directly to start screening.
Colorado1 site
- University of Colorado Anschutz Medical CampusAurora, Colorado
Washington2 sites
- University of WashingtonSeattle, Washington
- Providence Sacred Heart Medical CenterSpokane, Washington
Timeline
Started enrolling: 2024-04-05. Expected completion: 2027-12. Last updated on ClinicalTrials.gov: 2026-06-02.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
